Provenge Should Be "Very Familiar" To CMS Now, Dendreon Says About NCA
This article was originally published in The Pink Sheet Daily
Executive Summary
Dendreon comments on CMS' announcement that it would open a national coverage analysis, saying it is not needed given the amount of information the company already has provided on its new prostate cancer vaccine.